Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Statistical Methods for Clinical Trial Designs in the New Era of Cancer Treatment.

Guo B, Zhang R.

Biostat Biom Open Access J. 2018 Feb;5(3). pii: 555665. Epub 2018 Feb 28.

2.

Cell death-based treatment of lung adenocarcinoma.

Denisenko TV, Budkevich IN, Zhivotovsky B.

Cell Death Dis. 2018 Jan 25;9(2):117. doi: 10.1038/s41419-017-0063-y. Review.

3.

Preclinical Characterization of a Novel Monoclonal Antibody NEO-201 for the Treatment of Human Carcinomas.

Fantini M, David JM, Saric O, Dubeykovskiy A, Cui Y, Mavroukakis SA, Bristol A, Annunziata CM, Tsang KY, Arlen PM.

Front Immunol. 2018 Jan 4;8:1899. doi: 10.3389/fimmu.2017.01899. eCollection 2017.

4.

Activity and Immune Correlates of a Programmed Death-1 Blockade Antibody in the treatment of Refractory Solid Tumors.

Jiang C, Cai X, Zhang H, Xia X, Zhang B, Xia L.

J Cancer. 2018 Jan 1;9(1):205-212. doi: 10.7150/jca.21414. eCollection 2018.

5.

Metabolism-associated danger signal-induced immune response and reverse immune checkpoint-activated CD40+ monocyte differentiation.

Dai J, Fang P, Saredy J, Xi H, Ramon C, Yang W, Choi ET, Ji Y, Mao W, Yang X, Wang H.

J Hematol Oncol. 2017 Jul 24;10(1):141. doi: 10.1186/s13045-017-0504-1. Review.

6.

NKp46 Recognizes the Sigma1 Protein of Reovirus: Implications for Reovirus-Based Cancer Therapy.

Bar-On Y, Charpak-Amikam Y, Glasner A, Isaacson B, Duev-Cohen A, Tsukerman P, Varvak A, Mandelboim M, Mandelboim O.

J Virol. 2017 Sep 12;91(19). pii: e01045-17. doi: 10.1128/JVI.01045-17. Print 2017 Oct 1.

7.

Thymoquinone as a Potential Adjuvant Therapy for Cancer Treatment: Evidence from Preclinical Studies.

Mostofa AGM, Hossain MK, Basak D, Bin Sayeed MS.

Front Pharmacol. 2017 Jun 12;8:295. doi: 10.3389/fphar.2017.00295. eCollection 2017. Review.

8.

Phase II Study of Adjuvant Immunotherapy with the CSF-470 Vaccine Plus Bacillus Calmette-Guerin Plus Recombinant Human Granulocyte Macrophage-Colony Stimulating Factor vs Medium-Dose Interferon Alpha 2B in Stages IIB, IIC, and III Cutaneous Melanoma Patients: A Single Institution, Randomized Study.

Mordoh J, Pampena MB, Aris M, Blanco PA, Lombardo M, von Euw EM, Mac Keon S, YĆ©pez Crow M, Bravo AI, O'Connor JM, Orlando AG, Ramello F, Levy EM, Barrio MM.

Front Immunol. 2017 May 31;8:625. doi: 10.3389/fimmu.2017.00625. eCollection 2017.

9.

Epi-drugs in combination with immunotherapy: a new avenue to improve anticancer efficacy.

Mazzone R, Zwergel C, Mai A, Valente S.

Clin Epigenetics. 2017 May 30;9:59. doi: 10.1186/s13148-017-0358-y. eCollection 2017. Review.

10.

Toll-Like Receptor 9 Agonists for Cancer Therapy.

Melisi D, Frizziero M, Tamburrino A, Zanotto M, Carbone C, Piro G, Tortora G.

Biomedicines. 2014 Aug 4;2(3):211-228. doi: 10.3390/biomedicines2030211. Review.

11.

Immunotherapy for Head and Neck Squamous Cell Carcinoma: A Review of Current and Emerging Therapeutic Options.

Moskovitz JM, Moy J, Seiwert TY, Ferris RL.

Oncologist. 2017 Jun;22(6):680-693. doi: 10.1634/theoncologist.2016-0318. Epub 2017 May 15. Review.

PMID:
28507203
12.

Immune checkpoint proteins: exploring their therapeutic potential to regulate atherosclerosis.

Foks AC, Kuiper J.

Br J Pharmacol. 2017 Nov;174(22):3940-3955. doi: 10.1111/bph.13802. Epub 2017 May 4. Review.

PMID:
28369782
13.

Interleukin-2 in Renal Cell Carcinoma: A Has-Been or a Still-Viable Option?

Amin A, White RL.

J Kidney Cancer VHL. 2014 Nov 23;1(7):74-83. doi: 10.15586/jkcvhl.2014.18. eCollection 2014.

14.

Identifying and Targeting the Cause of Cancer is Needed to Cure Cancer.

Adjiri A.

Oncol Ther. 2016;4(1):17-33. doi: 10.1007/s40487-015-0015-6. Epub 2016 Jan 20. Review.

15.

Nivolumab as Programmed Death-1 (PD-1) Inhibitor for Targeted Immunotherapy in Tumor.

Guo L, Zhang H, Chen B.

J Cancer. 2017 Feb 10;8(3):410-416. doi: 10.7150/jca.17144. eCollection 2017. Review.

16.

Immunotherapy-associated autoimmune hemolytic anemia.

Khan U, Ali F, Khurram MS, Zaka A, Hadid T.

J Immunother Cancer. 2017 Feb 21;5:15. doi: 10.1186/s40425-017-0214-9. eCollection 2017.

17.

Myeloid cells as a target for oligonucleotide therapeutics: turning obstacles into opportunities.

Kortylewski M, Moreira D.

Cancer Immunol Immunother. 2017 Aug;66(8):979-988. doi: 10.1007/s00262-017-1966-2. Epub 2017 Feb 18. Review.

PMID:
28214929
18.

Minimum absolute lymphocyte counts during radiation are associated with a worse prognosis in patients with unresectable hepatocellular carcinoma.

Zhao Q, Xu X, Yue J, Zhu K, Feng R, Jiang S, Qi Z, Wang R.

Therap Adv Gastroenterol. 2017 Feb;10(2):231-241. doi: 10.1177/1756283X16685557. Epub 2016 Dec 29.

20.

Phase I study of Nivolumab, an anti-PD-1 antibody, in patients with malignant solid tumors.

Yamamoto N, Nokihara H, Yamada Y, Shibata T, Tamura Y, Seki Y, Honda K, Tanabe Y, Wakui H, Tamura T.

Invest New Drugs. 2017 Apr;35(2):207-216. doi: 10.1007/s10637-016-0411-2. Epub 2016 Dec 8.

Supplemental Content

Support Center